As has been elegantly reviewed by Toldo and Abbate20, recent experimental studies have focussed on the NLRP3 inflammasome as an important new therapeutic target to reduce reperfusion injury, infarct size, and prevent the development of HF following myocardial infarction. The gene discussed is NLRP3; the disease is hydrops fetalis.